Esmolol, commonly marketed under the trade name Brevibloc, is a cardioselective beta-1 receptor blocker. It has a rapid onset but short duration of action without causing significant intrinsic sympathomimetic or membrane stabilizing activities at recommended therapeutic doses. It works by blocking beta-adrenergic receptors in the heart, which leads to decrea...
For the rapid control of ventricular rate in patients with atrial fibrillation or atrial flutter in perioperative, postoperative, or other emergent circumstances where short term control of ventricular rate with a short-acting agent is desirable. Also used in noncompensatory sinus tachycardia where the rapid heart rate requires specific intervention.
Ain Shams University, Cairo, Egypt
Erasmus Medical Center, Rotterdam, Zuid Holland, Netherlands
Sichuan Provincial People's Hospital, Chengdu, Sichuan, China
Khon Kaen University, Khon Kaen, Naimuang, Muang, Thailand
Department of Intensive Care Medicine, Jinan, Shandong, China
Alexandria University Faculty of Medicin, Alexandria, Egypt
Qianfoshan Hospital, The First Hospital affiliated of Shandong First Medical University, Jinan, Shandong, China
E. Meshalkin National Medical Research Center, Novosibirsk, Russian Federation
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.